336 related articles for article (PubMed ID: 37376016)
1. Advancing Cancer Therapy with Copper/Disulfiram Nanomedicines and Drug Delivery Systems.
Kang X; Jadhav S; Annaji M; Huang CH; Amin R; Shen J; Ashby CR; Tiwari AK; Babu RJ; Chen P
Pharmaceutics; 2023 May; 15(6):. PubMed ID: 37376016
[TBL] [Abstract][Full Text] [Related]
2. Recent Advances in Repurposing Disulfiram and Disulfiram Derivatives as Copper-Dependent Anticancer Agents.
Kannappan V; Ali M; Small B; Rajendran G; Elzhenni S; Taj H; Wang W; Dou QP
Front Mol Biosci; 2021; 8():741316. PubMed ID: 34604310
[TBL] [Abstract][Full Text] [Related]
3. Diethyldithiocarbamate-copper nanocomplex reinforces disulfiram chemotherapeutic efficacy through light-triggered nuclear targeting.
Ren L; Feng W; Shao J; Ma J; Xu M; Zhu BZ; Zheng N; Liu S
Theranostics; 2020; 10(14):6384-6398. PubMed ID: 32483459
[TBL] [Abstract][Full Text] [Related]
4. Disulfiram's anti-cancer activity reflects targeting NPL4, not inhibition of aldehyde dehydrogenase.
Skrott Z; Majera D; Gursky J; Buchtova T; Hajduch M; Mistrik M; Bartek J
Oncogene; 2019 Oct; 38(40):6711-6722. PubMed ID: 31391554
[TBL] [Abstract][Full Text] [Related]
5. Old wine in new bottles: Advanced drug delivery systems for disulfiram-based cancer therapy.
McMahon A; Chen W; Li F
J Control Release; 2020 Mar; 319():352-359. PubMed ID: 31911155
[TBL] [Abstract][Full Text] [Related]
6. Targeting ALDH1A1 by disulfiram/copper complex inhibits non-small cell lung cancer recurrence driven by ALDH-positive cancer stem cells.
Liu X; Wang L; Cui W; Yuan X; Lin L; Cao Q; Wang N; Li Y; Guo W; Zhang X; Wu C; Yang J
Oncotarget; 2016 Sep; 7(36):58516-58530. PubMed ID: 27542268
[TBL] [Abstract][Full Text] [Related]
7. Disulfiram/Copper Suppresses Cancer Stem Cell Activity in Differentiated Thyroid Cancer Cells by Inhibiting BMI1 Expression.
Ni YL; Chien PJ; Hsieh HC; Shen HT; Lee HT; Chen SM; Chang WW
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362068
[TBL] [Abstract][Full Text] [Related]
8. Cannabidiol-induced activation of the metallothionein pathway impedes anticancer effects of disulfiram and its metabolite CuET.
Buchtova T; Skrott Z; Chroma K; Rehulka J; Dzubak P; Hajduch M; Lukac D; Arampatzis S; Bartek J; Mistrik M
Mol Oncol; 2022 Apr; 16(7):1541-1554. PubMed ID: 34632694
[TBL] [Abstract][Full Text] [Related]
9. Disulfiram's Anticancer Activity: Evidence and Mechanisms.
Jiao Y; Hannafon BN; Ding WQ
Anticancer Agents Med Chem; 2016; 16(11):1378-1384. PubMed ID: 27141876
[TBL] [Abstract][Full Text] [Related]
10. Disulfiram Copper Nanoparticles Prepared with a Stabilized Metal Ion Ligand Complex Method for Treating Drug-Resistant Prostate Cancers.
Chen W; Yang W; Chen P; Huang Y; Li F
ACS Appl Mater Interfaces; 2018 Dec; 10(48):41118-41128. PubMed ID: 30444340
[TBL] [Abstract][Full Text] [Related]
11. Disulfiram: A Food and Drug Administration-approved multifunctional role in synergistically drug delivery systems for tumor treatment.
Xu L; Sun Y; Li Y; Sun J; Guo Y; Shen Q; Wei Q; Shen JW
Int J Pharm; 2022 Oct; 626():122130. PubMed ID: 36007849
[TBL] [Abstract][Full Text] [Related]
12. Differential Cytotoxicity Mechanisms of Copper Complexed with Disulfiram in Oral Cancer Cells.
Chen SY; Chang YL; Liu ST; Chen GS; Lee SP; Huang SM
Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33918312
[TBL] [Abstract][Full Text] [Related]
13. Highly Stable, Coordinated Polymeric Nanoparticles Loading Copper(II) Diethyldithiocarbamate for Combinational Chemo/Chemodynamic Therapy of Cancer.
Peng X; Pan Q; Zhang B; Wan S; Li S; Luo K; Pu Y; He B
Biomacromolecules; 2019 Jun; 20(6):2372-2383. PubMed ID: 31117352
[TBL] [Abstract][Full Text] [Related]
14. Glutathione-responsive copper-disulfiram nanoparticles for enhanced tumor chemotherapy.
Chen M; Huang Z; Xia M; Ding Y; Shan T; Guan Z; Dai X; Xu X; Huang Y; Huang M; Zhao C
J Control Release; 2022 Jan; 341():351-363. PubMed ID: 34856225
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxic effect of disulfiram/copper on human cervical cancer cell lines and LGR5-positive cancer stem-like cells.
Cao HZ; Yang WT; Zheng PS
BMC Cancer; 2022 May; 22(1):521. PubMed ID: 35534815
[TBL] [Abstract][Full Text] [Related]
16. Leveraging disulfiram to treat cancer: Mechanisms of action, delivery strategies, and treatment regimens.
Lu Y; Pan Q; Gao W; Pu Y; Luo K; He B; Gu Z
Biomaterials; 2022 Feb; 281():121335. PubMed ID: 34979419
[TBL] [Abstract][Full Text] [Related]
17. Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.
Bista R; Lee DW; Pepper OB; Azorsa DO; Arceci RJ; Aleem E
J Exp Clin Cancer Res; 2017 Feb; 36(1):22. PubMed ID: 28143565
[TBL] [Abstract][Full Text] [Related]
18. Disulfiram/Copper induces antitumor activity against gastric cancer via the ROS/MAPK and NPL4 pathways.
Liu Y; Guan X; Wang M; Wang N; Chen Y; Li B; Xu Z; Fu F; Zheng Z; Du C
Bioengineered; 2022 Mar; 13(3):6579-6589. PubMed ID: 35290151
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effect on ovarian cancer ALDH+ stem-like cells by Disulfiram and Copper treatment through ALDH and ROS modulation.
Guo F; Yang Z; Kulbe H; Albers AE; Sehouli J; Kaufmann AM
Biomed Pharmacother; 2019 Oct; 118():109371. PubMed ID: 31545281
[TBL] [Abstract][Full Text] [Related]
20. Targeting cancer stem cells by disulfiram and copper sensitizes radioresistant chondrosarcoma to radiation.
Wang K; Michelakos T; Wang B; Shang Z; DeLeo AB; Duan Z; Hornicek FJ; Schwab JH; Wang X
Cancer Lett; 2021 May; 505():37-48. PubMed ID: 33582212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
